Urs Wiedemann is founder and Managing Partner of stradoo®. Before building up stradoo®, Urs Wiedemann was Partner of Cepton Strategies as well as the responsible Vice President of Charles River Associates’ continental European Life Science strategy consulting business. Besides his consulting activities, Dr. Wiedemann is an independent investor, advisor, and board member for life sciences and technology companies.
At stradoo, Urs is a dedicated expert on pharmaceutical and biotech corporate and R&D strategy as well as in (competitive) product positioning and optimizing go–to–market models. He has led numerous projects on Therapeutic Area strategies, Rare Disease strategies, Portfolio Management as well as Launch and Selling Excellence.
Urs majored in molecular biology at LMU Munich, with a focus on genetics, microbiology, and immunology. After his studies, he worked within the pharmaceuticals industry in global R&D. He completed his Ph.D. in Biochemistry at the Free University, Berlin, developing theoretical models using state-of-the-art statistical and AI methodologies. After his scientific career, Urs switched to strategy consulting where he has been responsible for manifold projects covering a broad range from early scientific innovations strategy to optimizing go–to–market models for leading global industry players, highly innovative startup companies as well as financial investors since then.
